[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathologic-processes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathologic-processes":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,78,106,143,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100474012","testing-virtues-patient-care-sets-in-cardiac-patients-virtues-cardiac-care-100474012",false,"NCT05452356","Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)","Testing of Patient Care Sets and Management of Cardiovascular Conditions Using a Virtual Platform","VIRTUES-CC","Inclusion Criteria:\n\n* Any patient with a cardiovascular condition.\n* Ability to provide informed consent.\n* Proficient in the English language.\n* Access to a device capable of running mobile application.\n* Used mobile technology within the past 3 months.\n\nExclusion Criteria:\n\n* Any medical condition making 1-month survival unlikely.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Patients with various cardiac conditions (such as those who experience a heart attack) are increasing in Canada and are in need of appropriate cardiac rehabilitation and care. Many patients do not have access to local in-person cardiac clinics, particularly in rural regions of Canada. A user-friendly digital application with accessible educational resources and recommendations based on the most up to date clinical practice guidelines can help mitigate these issues. VIRTUES is a digital healthcare application that targets 11 modifiable modules as follows:\n\n1. antithrombotic management\n2. lipid management\n3. rate and rhythm control for atrial fibrillation\n4. heart failure care\n5. post myocardial infarction care\n6. blood sugar management\n7. blood pressure management\n8. physical activity\n9. healthy eating\n10. smoking cessation\n11. alcohol reduction\n\nOf the 11 total modules, the first 7 listed provide recommendations in VIRTUES. The remaining 4 (physical activity, healthy eating, smoking cessation and alcohol reduction) consist of simple referrals to existing recommendations (i.e., for healthy eating and physical exercise) and referrals to existing local programs (i.e., for smoking cessation and alcohol reduction). Thus, in this cohort study, the investigators will test the primary 7 modules with 200 patients per module for approximately one month each in order to obtain feedback on the usability of each module. The investigators will also conduct virtual focus group discussions to obtain open ended feedback on the application. This study will provide valuable feedback, which will be used to improve and adapt the VIRTUES platform.",[25,26,27,28,29],"Heart Diseases","Arrhythmias, Cardiac","Atrial Fibrillation","Cardiovascular Diseases","Pathologic Processes","RECRUITING","2026-05-19",{"date":33,"type":34},"2026-05-22","ACTUAL",{"date":36,"type":34},"2024-04-18",{"date":38,"type":21},"2028-09-30",{"name":40,"class":41},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":64,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100536954","phase-4-evaluation-of-efficacy-of-skl-pro-powder-on-symptoms-of-irritable-bowel-syndrome-100536954","NCT06271538","Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome","A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* IBS diagnosed using the Rome IV criteria\n* Age above 18 years old and any gender\n* Any subtypes of IBS (diarrhea, constipation or mixed)\n\nExclusion Criteria:\n\n* Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)\n* Was prescribed antibiotic (s) within the past one month\n* Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy\n* Presence of bowel malignancy\n* Diagnosis of bowel infection within the past one month\n* Previous abdominal surgeries\n* Patients with overt psychiatric illnesses including schizophrenia and manic disorders\n* A history of allergy to probiotic\n* Was prescribed probiotic (s) within the past one month\n* Was previously prescribed probiotic Skal Pro™ (LP299V™)",{"count":51,"type":21},60,"INTERVENTIONAL",[54],"PHASE4","The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.",[57,58,59,60,61,29,62,63],"Irritable Bowel Syndrome","Gastrointestinal Diseases","Colonic Diseases, Functional","Intestinal Disease","Digestive System Disease","Colonic Disease","Disease",[65,66,67],"probiotic","Lactobacillus plantarum 299v","randomized controlled study","2026-05-11",{"date":70,"type":34},"2026-05-12",{"date":72,"type":34},"2024-10-17",{"date":74,"type":21},"2026-06-30",{"name":76,"class":77},"EP Plus Group Sdn Bhd","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":52,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":42},"100535461","maximizing-lymph-node-dissection-on-fresh-and-fixed-lung-cancer-resection-specimens-100535461","NCT06252129","Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens","Inclusion Criteria:\n\n1. Subjects with a lung nodule or mass who are eligible to undergo a lobectomy.\n2. Subject without any metastasis present.\n3. Subjects who have peripheral lung nodule location\n4. Subjects must be 18 years of age or older.\n\nExclusion Criteria:\n\n1. Subjects who received preoperative chemotherapy or radiotherapy.\n2. Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.",true,{"count":86,"type":21},160,[88],"NA","Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.",[91,92,29],"Lung Cancer","Lymph Node Metastasis",[94,95,96],"NSCLC","Lymph node dissection","Lung cancer staging","2026-03-03",{"date":99,"type":34},"2026-03-05",{"date":101,"type":34},"2024-07-26",{"date":103,"type":21},"2027-12",{"name":105,"class":41},"Brigham and Women's Hospital",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":52,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100382220","phase-3-perioperative-respiratory-care-and-outcomes-for-patients-undergoing-high-risk-abdominal-surgery-100382220","NCT04256798","Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery","PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries","PENGUIN","Inclusion Criteria:\n\n* Adults and children aged 10 years or over\n* Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length\n* Written informed consent of patient (signature or a fingerprint)\n\nExclusion Criteria:\n\n* Patients undergoing caesarean section\n* Patients with a documented or suspected allergy to chlorhexidine\n* Patient unable to complete postoperative follow-up (not contactable after discharge)\n* Previous enrolment in PENGUIN within the past 30 days\n* American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)","10 Years","100 Years",{"count":117,"type":21},12942,[119],"PHASE3","PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.\n\nPatients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.",[122,123,124,125,126,127,128,129,29,130,131,132],"Infection","Pneumonia","Surgical Site Infection","Wound Infection","Surgical Wound Infection","Postoperative Complications","Anesthesia","Communicable Disease","Perioperative Complication","Chlorhexidine","Laparotomy","2025-02-18",{"date":135,"type":34},"2025-02-19",{"date":137,"type":34},"2020-11-13",{"date":139,"type":21},"2026-06-01",{"name":141,"class":41},"University of Birmingham",37,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":52,"phases":153,"briefSummary":154,"conditions":155,"keywords":173,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":183,"leadSponsor":185,"locationsCount":42},"100567960","clinical-trial-assessing-human-placental-membrane-products-and-standard-of-care-versus-standard-of-care-in-nonhealing-dfus-and-vlus-100567960","NCT06674980","Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs","A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.","C5CAMP","Inclusion Criteria for DFU:\n\n1. At least 18 years of age or older.\n2. Must have diagnosis of type 1 or 2 Diabetes mellitus.\n3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.\n4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.\n5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.\n6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.\n7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and \\\u003C= 1.3\n   2. TBI \\>= 0.6\n   3. TCOM \\>= 40 mmHg\n   4. PVR: biphasic\n8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment.\n10. Subject must consent to using the prescribed offloading method for the duration of the study.\n11. Subject must agree to attend weekly study visits.\n12. Subject must be willing and able to participate in the consent process.\n\nExclusion Criteria for DFU:\n\n1. Subject is known to have a life expectancy of \\\u003C 6 months.\n2. Subject's target ulcer is not secondary to diabetes.\n3. Target ulcer is infected or there is cellulitis in the surrounding skin.\n4. Target ulcer exposes tendon or bone.\n5. Evidence of osteomyelitis complicating the target ulcer.\n6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. Subject is taking hydroxyurea.\n9. Subject has applied topical steroids to the ulcer surface within one month of initial screening.\n10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase.\n14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months.\n16. Subject has end stage renal disease requiring dialysis.\n17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening.\n20. Subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n\nInclusion Criteria for VLU:\n\nPotential subjects are required to meet all the following criteria for enrollment in the study.\n\n1. Subjects must be at least 18 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.\n4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria for VLU:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. Women who are pregnant or considering becoming pregnant within the next 6 months.\n11. The potential subject has end stage renal disease requiring dialysis.\n12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.\n13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n15. The subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n16. A subject has a wound with active or latent infection is excluded.\n17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.",{"count":152,"type":21},177,[88],"The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.",[29,156,157,158,159,160,161,28,162,163,164,165,166,167,168,169,170,171,172],"Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Disease","Diabetic Angiopathies","Vascular Diseases","Leg Ulcer","Skin Ulcer","Skin Diseases","Diabetes Complications","Diabetic Neuropathies","Foot Diseases","Diabetic Foot","Foot Ulcer","Diabetes Mellitus, Type 2","Ulcer","Foot Ulcer Unhealed",[174,175,176,177,178],"Human Placental Membrane (HPM)","Diabetic Foot Ulcer (DFU)","Venous Leg Ulcer (VLU)","Cellular, Acellular, and Matrix-like Product (CAMP)","Cellular and\u002For Tissue-Based Product (CTP)","2024-12-20",{"date":181,"type":34},"2024-12-27",{"date":179,"type":34},{"date":184,"type":21},"2027-01-22",{"name":186,"class":77},"C5 Biomedical",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":52,"phases":197,"briefSummary":199,"conditions":200,"keywords":207,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100513730","phase-2-umbilical-mesenchymal-stromal-cells-as-cellular-immunotherapy-for-septic-shock-100513730","NCT05969275","Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock","Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Multi-Center, Double Blind, Phase II Randomized Controlled Trial","UC-CISSII","Inclusion Criteria:\n\nA participant must meet all the following inclusion criteria at time of randomization to be eligible:\n\n1. At least 18 years of age AND\n2. Requirement for admission to the intensive care unit AND\n3. Index admission to the intensive care unit AND\n4. Cardiovascular organ failure for at least 1 consecutive hour defined by the requirement of at least 5 mcg\u002Fmin of norepinephrine or 100 mcg\u002Fmin of phenylephrine or 0.03 U\u002Fmin vasopressin AND\n5. Clinician impression that cardiovascular organ failure is related to infection AND\n6. There is at least 1 other acute organ failure according to modified individual Sequential Organ Failure Assessment Scores within 24 hours of meeting Cardiovascular organ failure defined by:\n\n   1. Respiratory failure: invasive or non-invasive mechanical ventilation with a positive end expiratory pressure (PEEP) \\>\u002F= 5 cm H2O and a partial pressure of oxygen\u002Ffractional inspired oxygen concentration (P\u002FF ratio \\\u003C\u002F= 200), OR high-flow nasal canula oxygen therapy (minimum total flow rate of 30 lpm and 40% FiO2); OR\n   2. Hematological failure: platelet count of \\\u003C\u002F= 100 X 10\\^9\u002FL OR\n   3. Acute kidney injury: acute renal insufficiency with a creatinine of \\>\u002F= 200 umol\u002FL, or the requirement for new renal replacement therapy, or for participants with known chronic renal failure but not on dialysis, a 50% increase in their baseline creatinine concentration OR\n   4. Organ hypoperfusion: a lactate \\>\u002F= 4 mmol\u002FL\n\nAcute organ failures that meet eligibility criteria must not have been present for greater than 48 hours prior to meeting the eligibility criteria.\n\nExclusion Criteria:\n\nPatients will be excluded if they have at least one of the following at time of randomization:\n\n1. Another form of shock (cardiogenic, hypovolemic, obstructive) OR\n2. History of known chronic pulmonary hypertension with a WHO functional class of IV OR\n3. History of severe chronic pulmonary disease requiring home oxygen OR\n4. History of severe chronic cardiac disease including congestive heart failure or valvular dysfunction with a New York Heart Association Functional class IV or severe chronic ischemic heart disease with a Canadian Cardiovascular Society angina class score IV OR\n5. History of severe chronic liver disease (Child-Pugh Class C or model for end stage liver disease (MELD) Score \\>= 15) OR\n6. Malignancy in previous 1 year (excluding resolved non-melanoma skin cancer) OR\n7. Treating physician impression that death is imminent within the 12 hours after meeting eligibility criteria OR\n8. Pregnant or lactating OR\n9. Family or patient not committed to aggressive care",{"count":196,"type":21},296,[198],"PHASE2","Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients with septic shock. The Cellular Immunotherapy for Septic Shock Phase I (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (UC-CISS II) at several Canadian academic centres which will evaluate intermediate measures of clinical efficacy (primary outcome), as well as biomarkers, safety, clinical outcome measures, and a health economic analysis (secondary outcomes).",[201,202,29,203,204,205,206],"Septic Shock","Sepsis","Shock","Systemic Inflammatory Response Syndrome","Inflammation","Infections",[208,209,210,211,212,213,214,202,201],"Mesenchymal Stem Cells","Mesenchymal Stromal Cells","Randomized Controlled Trial","Cryopreserved","Allogeneic","Umbilical Cord","Phase II","2024-12-04",{"date":217,"type":34},"2024-12-05",{"date":219,"type":34},"2024-02-14",{"date":221,"type":21},"2027-03-31",{"name":223,"class":41},"Ottawa Hospital Research Institute",2]